{"organizations": [], "uuid": "2e7eb029bf80259f7d8975612b8d19e9ce87ea8c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180117.html", "section_title": "Archive News &amp; Video for Wednesday, 17 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pharming-announces-fda-acceptance/brief-pharming-announces-fda-acceptance-for-review-of-supplemental-biologics-license-application-idUSASM000I74", "country": "US", "domain_rank": 408, "title": "BRIEF-Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.985, "site_type": "news", "published": "2018-01-17T14:27:00.000+02:00", "replies_count": 0, "uuid": "2e7eb029bf80259f7d8975612b8d19e9ce87ea8c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pharming-announces-fda-acceptance/brief-pharming-announces-fda-acceptance-for-review-of-supplemental-biologics-license-application-idUSASM000I74", "ord_in_thread": 0, "title": "BRIEF-Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "fda acceptance for review of supplemental biologics", "sentiment": "negative"}, {"name": "pharming", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 17 (Reuters) - PHARMING GROUP NV:\n* PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS\n* ‍FDA INDICATED SBLA IS SUFFICIENTLY COMPLETE TO PERMIT SUBSTANTIVE REVIEW\n* ‍FDA SET AN ACTION DATE OF SEPTEMBER 21, 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-17T14:27:00.000+02:00", "crawled": "2018-01-18T16:10:55.000+02:00", "highlightTitle": ""}